CN103476415B - 用于增强成体干细胞的不对称分裂的cbp/连环蛋白拮抗剂 - Google Patents

用于增强成体干细胞的不对称分裂的cbp/连环蛋白拮抗剂 Download PDF

Info

Publication number
CN103476415B
CN103476415B CN201180065118.7A CN201180065118A CN103476415B CN 103476415 B CN103476415 B CN 103476415B CN 201180065118 A CN201180065118 A CN 201180065118A CN 103476415 B CN103476415 B CN 103476415B
Authority
CN
China
Prior art keywords
application according
catenin
cbp
alkyl
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180065118.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN103476415A (zh
Inventor
迈克尔·卡恩
张嘉玲
迈克尔·麦克米伦
赵义
吴永丰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Publication of CN103476415A publication Critical patent/CN103476415A/zh
Application granted granted Critical
Publication of CN103476415B publication Critical patent/CN103476415B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)
CN201180065118.7A 2010-11-16 2011-11-16 用于增强成体干细胞的不对称分裂的cbp/连环蛋白拮抗剂 Active CN103476415B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US41433410P 2010-11-16 2010-11-16
US41434810P 2010-11-16 2010-11-16
US61/414,348 2010-11-16
US61/414,334 2010-11-16
US201161545033P 2011-10-07 2011-10-07
US61/545,033 2011-10-07
PCT/US2011/061062 WO2012068299A2 (en) 2010-11-16 2011-11-16 Cbp/catenin antagonists for enhancing asymmetric division of somatic stem cells

Publications (2)

Publication Number Publication Date
CN103476415A CN103476415A (zh) 2013-12-25
CN103476415B true CN103476415B (zh) 2017-09-22

Family

ID=46084627

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180065118.7A Active CN103476415B (zh) 2010-11-16 2011-11-16 用于增强成体干细胞的不对称分裂的cbp/连环蛋白拮抗剂

Country Status (10)

Country Link
US (1) US10092568B2 (https=)
EP (1) EP2640393B1 (https=)
JP (2) JP6163105B2 (https=)
KR (1) KR102077871B1 (https=)
CN (1) CN103476415B (https=)
AU (2) AU2011329854B2 (https=)
BR (1) BR112013012228B1 (https=)
CA (1) CA2817975C (https=)
ES (1) ES2935544T3 (https=)
WO (1) WO2012068299A2 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102077871B1 (ko) * 2010-11-16 2020-02-14 유니버시티 오브 써던 캘리포니아 체세포 줄기 세포의 비대칭 분열을 향상시키기 위한 ｃｂｐ/카테닌 길항제
HK1201061A1 (en) 2011-10-07 2015-08-21 University Of Southern California Cbp/catenin antagonists for enhancing asymmetric division of somatic stem cells
WO2014025832A1 (en) * 2012-08-06 2014-02-13 University Of Southern California Wnt modulators for the protection, mitigation and treatment of radiation injury
EP2916844A1 (en) * 2012-10-19 2015-09-16 Prism Pharma Co., Ltd. Methods for treating eye disorders
US20160166577A1 (en) * 2012-10-19 2016-06-16 Prism Pharma Co., Ltd. Treatment of pulmonary fibrosis using an inhibitor of cbp/catenin
US20150274751A1 (en) * 2012-10-19 2015-10-01 Prism Pharma Co., Ltd. Treatment of scleroderma using an inhibitor of cbp/catenin
JP2016502497A (ja) * 2012-10-19 2016-01-28 株式会社ＰＲＩＳＭ Ｐｈａｒｍａ Ｉ型およびｉｉ型糖尿病を治療する方法
CN104902901A (zh) * 2012-10-19 2015-09-09 株式会社棱镜制药 使用cbp/连环蛋白的抑制剂治疗过度增殖性和癌前皮肤病
WO2014061825A1 (en) * 2012-10-19 2014-04-24 Hiroyuki Kouji Treatment of viral and infectious diseases using an inhibitor of cbp/catenin
WO2014194200A1 (en) 2013-05-30 2014-12-04 Creasey Graham H Topical neurological stimulation
US11229789B2 (en) 2013-05-30 2022-01-25 Neurostim Oab, Inc. Neuro activator with controller
CN104231048B (zh) * 2013-06-05 2017-05-24 财团法人工业技术研究院 生发胜肽及药物组合物
EP3129026A4 (en) * 2014-04-11 2018-01-10 Bcs Business Consulting Services Pte Ltd Hair enhancing formulation
RU2549987C1 (ru) * 2014-06-17 2015-05-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Средство для ускорения заживления ран и регенерации тканей
US11077301B2 (en) 2015-02-21 2021-08-03 NeurostimOAB, Inc. Topical nerve stimulator and sensor for bladder control
WO2017025963A1 (en) * 2015-08-10 2017-02-16 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Methods and pharmaceutical compositions for improving wound healing using cd24
WO2017044302A1 (en) * 2015-09-09 2017-03-16 Rush University Medical Center Compositions and methods for treating bone diseases
WO2017047762A1 (ja) * 2015-09-18 2017-03-23 国立大学法人鳥取大学 低分子化合物による癌と線維化の抑制と再生促進の効果
PT3320901T (pt) * 2016-01-28 2020-04-24 Tianjin Int Joint Academy Of Biotechnology & Medicine Dimetilaminomicheliolida para utilização no tratamento de fibrose pulmonar
CN105854018B (zh) * 2016-03-28 2018-11-13 杭州师范大学 Wnt抑制剂在制备治疗造血再生障碍性疾病药物中的应用
US20190125753A1 (en) * 2016-04-20 2019-05-02 University Of Southern California Compounds and methods for increasing hematopoiesis
EP3655961A4 (en) * 2017-07-17 2021-09-01 Massachusetts Institute of Technology HEALTHY AND SICK BARRIER TISSUE CELL ATLAS
EP3706856A4 (en) 2017-11-07 2021-08-18 Neurostim Oab, Inc. NON-INVASIVE NERVOUS ACTIVATOR WITH ADAPTIVE CIRCUIT
JP7605576B2 (ja) 2018-07-25 2024-12-24 ポーラ化成工業株式会社 皮膚老化改善剤のスクリーニング方法
US11458311B2 (en) 2019-06-26 2022-10-04 Neurostim Technologies Llc Non-invasive nerve activator patch with adaptive circuit
KR20220115802A (ko) 2019-12-16 2022-08-18 뉴로스팀 테크놀로지스 엘엘씨 부스트 전하 전달 기능이 있는 비침습적 신경 액티베이터
KR102612610B1 (ko) * 2020-02-07 2023-12-12 주식회사 한스파마 신경줄기세포의 제조방법 및 이로부터 얻어진 신경줄기세포 배양액을 유효성분으로 포함하는 피부 재생, 항산화, 항염증 및 상처 치료용 조성물
WO2021183791A1 (en) 2020-03-12 2021-09-16 City Of Hope Wnt/cbp/catenin signaling pathway inhibitors and uses thereof
AR121544A1 (es) 2020-03-12 2022-06-15 3 2 Pharma Inhibidores de la vía de señalización por cbp / catenina y sus usos
CA3194606A1 (en) * 2020-10-05 2022-04-14 Fuqiang Ruan Topical agents for dermatological applications
US20230390296A1 (en) * 2020-10-30 2023-12-07 Keio University Novel treatment and prevention of sarcopenia-related diseases
WO2023114456A1 (en) * 2021-12-17 2023-06-22 Athira Pharma, Inc. Uses of bicyclic compounds for the treatment of diseases
JP7178143B1 (ja) 2022-03-17 2022-11-25 学校法人関西医科大学 爪幹細胞及び毛髪の成長を助長する外用剤
AU2023366929A1 (en) 2022-10-25 2025-05-08 Veradermics, Incorporated Compositions and methods of use for modified release minoxidil

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1333270A (zh) * 2000-07-07 2002-01-30 上海博德基因开发有限公司 一种新的多肽——人cbp20蛋白47.74和编码这种多肽的多核苷酸
CN101130799A (zh) * 2007-08-06 2008-02-27 大连理工大学 利用几丁质生产生物能源物质的方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84414A0 (en) 1986-11-14 1988-04-29 Ciba Geigy Ag N9-cyclopentyl-substituted adenine derivatives
US5262321A (en) 1991-05-31 1993-11-16 Dana-Farber Cancer Institute DNA encoding p107 tumor suppressor
US5750336A (en) 1994-02-10 1998-05-12 The Salk Institute For Biological Studies Assays for the identification of compounds which inhibit activation of cAMP and mitogen responsive genes
US5658784A (en) 1994-04-14 1997-08-19 Dana-Farber Cancer Institute, Inc. Nucleic acid encoding transcription factor p300 and uses of p300
IT1271007B (it) 1994-09-13 1997-05-26 Zambon Spa Derivati del 2-ammino-1,2,3,4-tetraidronaftalene attivi sul sistema cardiovascolare
US6184223B1 (en) 1995-10-27 2001-02-06 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
CA2317505C (en) 1998-01-23 2011-01-04 Newbiotics, Inc. Enzyme catalyzed therapeutic agents
CA2409063A1 (en) 2000-05-15 2001-11-22 Mark L. Nelson 7-substituted fused ring tetracycline compounds
US20040072831A1 (en) 2001-10-12 2004-04-15 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7232822B2 (en) 2001-10-12 2007-06-19 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7671054B1 (en) 2001-10-12 2010-03-02 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7576084B2 (en) 2001-10-12 2009-08-18 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7566711B2 (en) 2001-10-12 2009-07-28 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
TW200304371A (en) 2002-02-22 2003-10-01 Akzo Nobel Nv Substituted 10-ary1-11H-benzo [b] fluorenes and 7-ary1-5, 6-dihydro-benz [a] anthracenes for selective effects on estrogen receptors
US6762185B1 (en) * 2002-03-01 2004-07-13 Choongwae Pharma Corporation Compounds useful for treatment of cancer, compositions containing the same, and methods of their use
CA2502644A1 (en) 2002-10-17 2004-04-29 Myriad Genetics, Inc. Reverse-turn mimetics and composition and methods relating thereto
EP1660502A2 (en) 2003-08-28 2006-05-31 Choongwae Pharma Corporation MODULATION OF ß-CATENIN/TCF ACTIVATED TRANSCRIPTION
JP3722146B1 (ja) 2004-06-16 2005-11-30 セイコーエプソン株式会社 プロジェクタおよび画像補正方法
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
US7563825B1 (en) 2005-03-18 2009-07-21 Choongwae Pharma Corporation Modulation of beta-catenin coactivator interactions to effect stem cell growth or differentiation
US7915251B2 (en) * 2005-03-18 2011-03-29 Institute For Chemical Genomics Alpha-helix mimetics and methods relating to the treatment of fibrosis
WO2007056513A1 (en) 2005-11-08 2007-05-18 Institute For Chemical Genomics α-HELIX MIMETICS AND METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS
WO2007062243A2 (en) * 2005-11-28 2007-05-31 Choongwae Pharma Corporation Serum-free expansion of cells in culture
JP2009538903A (ja) 2006-05-30 2009-11-12 チュンウェ ファーマ コーポレーション 幹細胞分化の誘導または抑制のための組成物
SG174100A1 (en) 2006-09-08 2011-09-29 Genentech Inc Wnt antagonists and their use in the diagnosis and treatment of wnt-mediated disorders
CN102186853A (zh) * 2008-10-14 2011-09-14 株式会社棱镜生物实验室 治疗癌症α-螺旋模拟物
JP5802195B2 (ja) * 2009-04-27 2015-10-28 オタワ ホスピタル リサーチ インスティチュート 幹細胞を調節するための組成物および方法ならびにその使用
US9040531B2 (en) 2009-05-07 2015-05-26 Prism BioLab Co., Ltd. Alpha helix mimetics and methods relating thereto
KR102077871B1 (ko) * 2010-11-16 2020-02-14 유니버시티 오브 써던 캘리포니아 체세포 줄기 세포의 비대칭 분열을 향상시키기 위한 ｃｂｐ/카테닌 길항제
US20140051706A1 (en) 2011-02-25 2014-02-20 Prism Pharma Co., Ltd. Alpha helix mimetics and methods relating thereto

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1333270A (zh) * 2000-07-07 2002-01-30 上海博德基因开发有限公司 一种新的多肽——人cbp20蛋白47.74和编码这种多肽的多核苷酸
CN101130799A (zh) * 2007-08-06 2008-02-27 大连理工大学 利用几丁质生产生物能源物质的方法

Also Published As

Publication number Publication date
AU2011329854B2 (en) 2017-03-30
EP2640393B1 (en) 2022-10-12
US10092568B2 (en) 2018-10-09
KR20130140079A (ko) 2013-12-23
KR102077871B1 (ko) 2020-02-14
JP2017088633A (ja) 2017-05-25
WO2012068299A9 (en) 2013-06-20
EP2640393A2 (en) 2013-09-25
JP6518706B2 (ja) 2019-05-22
AU2017201750B2 (en) 2019-01-17
CA2817975A1 (en) 2012-05-24
AU2017201750A1 (en) 2017-03-30
CA2817975C (en) 2020-03-31
BR112013012228A2 (pt) 2021-05-18
WO2012068299A2 (en) 2012-05-24
BR112013012228B1 (pt) 2023-02-28
EP2640393A4 (en) 2015-05-27
AU2017201750B9 (en) 2019-01-31
US20130280233A1 (en) 2013-10-24
CN103476415A (zh) 2013-12-25
JP6163105B2 (ja) 2017-07-12
AU2011329854A1 (en) 2013-07-04
ES2935544T3 (es) 2023-03-07
JP2013542999A (ja) 2013-11-28

Similar Documents

Publication Publication Date Title
CN103476415B (zh) 用于增强成体干细胞的不对称分裂的cbp/连环蛋白拮抗剂
CN103958517B (zh) 用于增强成体干细胞的不对称分裂的cbp/连环蛋白拮抗剂
Shi et al. Distinct roles of Wnt/β‐catenin signaling in the pathogenesis of chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis
B. Uzdensky et al. Signal transduction in human cutaneous melanoma and target drugs
Lu et al. Induction of inflammatory cytokines by a keratin mutation and their repression by a small molecule in a mouse model for EBS
Yang et al. ALKBH5 ameliorated liver fibrosis and suppressed HSCs activation via triggering PTCH1 activation in an m6A dependent manner
EP2512468B1 (en) METHOD OF TREATING SCARS AND ß-CATENIN-MEDIATED DISORDERS USING NEFOPAM COMPOUNDS
Patel et al. A WNT mimetic with broad spectrum FZD-specificity decreases fibrosis and improves function in a pulmonary damage model
EP3221284B1 (en) 13-cis-ramba retinamides that degrade mnks for treating cancer
RU2692785C1 (ru) Способы уменьшения кахексии, связанной с раком
KR102168006B1 (ko) 체세포 줄기 세포의 비대칭 분열을 향상시키기 위한 ｃｂｐ/카테닌 길항제
Kalogeropoulou Investigation of (bio) isosterism in anti-fibrotic “leads”
TW202126631A (zh) 作為klk5/7雙重抑制劑之苯并酮化合物
HK1224224B (zh) 使用奈福泮化合物治疗侵袭型纤维瘤病和β-联蛋白介导的疾病的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant